Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAltamira Therapeutics Ltd. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 06/28/2023 | Q2 2023 | -$12.91 | $52,735 | |||
| 03/30/2023 | Q1 2023 | -$12.97 | $52,735 | |||
| 05/16/2023 | Q4 2022 | -$2.89 | $0 | |||
| 09/29/2022 | Q3 2022 | -$199.86 | $-458,691 | |||
| 11/30/2022 | Q2 2022 | -$106.32 | $145,399 | |||
| 11/30/2022 | Q1 2022 | -$106.32 | $145,399 | |||
| 04/12/2022 | Q4 2021 | $164.89 | $0 | |||
| 09/29/2021 | Q3 2021 | -$149.92 | $0 | |||
| 03/31/2021 | Q2 2021 | -$108.47 | $0 | |||
| 03/31/2021 | Q1 2021 | -$108.47 | $0 | |||
| 03/31/2021 | Q4 2020 | -$148.91 | $237,000 | |||
| 09/29/2020 | Q3 2020 | -$148.91 | $0 | |||
| 09/17/2020 | Q2 2020 | -$115.96 | $0 | |||
| 09/17/2020 | Q1 2020 | -$115.96 | $0 | |||
| 04/16/2020 | Q4 2019 | -$83.44 | $-56,000 | |||
| 09/29/2019 | Q3 2019 | $0.00 | $0 | |||
| 06/30/2019 | Q2 2019 | -$165.85 | $0 | |||
| 03/30/2019 | Q1 2019 | $0.00 | $0 | |||
| 03/14/2019 | Q4 2018 | -$485.21 | $1.27 M | |||
| 09/30/2018 | Q3 2018 | -$569.22 | $0 |
Altamira Therapeutics Ltd. Earnings: FAQ's
How can I listen to Altamira Therapeutics Ltd.'s earnings conference
call?
The conference call for Altamira Therapeutics Ltd.'s latest earnings report can be listened to online.
How can I read Altamira Therapeutics Ltd.'s conference call transcript?
The conference call transcript for Altamira Therapeutics Ltd.'s latest earnings report can be read online.
How much profit does Altamira Therapeutics Ltd. generate each year?
Altamira Therapeutics Ltd. (:EARS) has a recorded net income of $0. Altamira Therapeutics Ltd. has generated $-14.81 earnings per share over the last four quarters.
What is Altamira Therapeutics Ltd.'s price-to-earnings ratio?
Altamira Therapeutics Ltd. (:EARS) has a price-to-earnings ratio of -0.02 and price/earnings-to-growth ratio is -0.